SCNN1G
Epithelial sodium channel subunit gamma
As of the edition of 20 October 2026, SCNN1G (epithelial sodium channel subunit gamma, UniProt P51170) has 1 drug tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P51170
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Inherited and neonatal; Lungs and airways; Digestive system; Ear, nose and throat
- Registered trials of its drugs
- 4
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Idrevloride | Went quiet | Phase 2 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 2 |
| Total on the list | 2 |